Estimates Revisions Verastem, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 29/07/2026 BST			5-day change	1st Jan Change
6.010 ^USD	-3.53%		+0.17%	-22.15%

07-28	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer	CI
07-22	Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.	1y. EPS revision
	VERASTEM, INC.
	ARGENX SE
	WUXI APPTEC CO., LTD.
	BIONTECH SE
	INSMED INCORPORATED
	WUXI BIOLOGICS (CAYMAN) INC.
	GENMAB A/S
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
	PHARMAESSENTIA CORPORATION
	EXELIXIS, INC.
	Average
	Weighted average by Cap.